From SARS to MERS, Thrusting Coronaviruses into the Spotlight
暂无分享,去创建一个
Chuan Qin | Pin Yu | L. Bao | C. Qin | Hua Zhu | Yanfeng Xu | Linlin Bao | Yanfeng Xu | Yajin Qu | Zhiqi Song | Wenjie Zhao | Yunlin Han | Hua Zhu | Ling Zhang | Yunlin Han | Ling Zhang | Pin Yu | Zhiqi Song | Wenjie Zhao | Yajin Qu
[1] T. Kuiken,et al. Pathology of Experimental SARS Coronavirus Infection in Cats and Ferrets , 2008, Veterinary pathology.
[2] L. Bao,et al. Comparative pathology of rhesus macaque and common marmoset animal models with Middle East respiratory syndrome coronavirus , 2017, PloS one.
[3] Xi Rao,et al. Identification of Two Critical Amino Acid Residues of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Its Variation in Zoonotic Tropism Transition via a Double Substitution Strategy , 2005, Journal of Biological Chemistry.
[4] B. Murphy,et al. Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters , 2005, Journal of Virology.
[5] J. Lepault,et al. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[6] Obi L. Griffith,et al. The Genome Sequence of the SARS-Associated Coronavirus , 2003, Science.
[7] T. Slezak,et al. Cynomolgus Macaque as an Animal Model for Severe Acute Respiratory Syndrome , 2006, PLoS medicine.
[8] D. Hui,et al. Middle East respiratory syndrome , 2015, The Lancet.
[9] N. Zhong,et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque , 2005, Nature Medicine.
[10] Jiang Gu,et al. Pathology and Pathogenesis of Severe Acute Respiratory Syndrome , 2007, The American Journal of Pathology.
[11] Ralph S. Baric,et al. A decade after SARS: strategies for controlling emerging coronaviruses , 2013, Nature Reviews Microbiology.
[12] Shibo Jiang,et al. Cross-Neutralization of Human and Palm Civet Severe Acute Respiratory Syndrome Coronaviruses by Antibodies Targeting the Receptor-Binding Domain of Spike Protein , 2006, The Journal of Immunology.
[13] Jincun Zhao,et al. Evasion by Stealth: Inefficient Immune Activation Underlies Poor T Cell Response and Severe Disease in SARS-CoV-Infected Mice , 2009, PLoS pathogens.
[14] A. Osterhaus,et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.
[15] N. Espina,et al. Mice Susceptible to SARS Coronavirus , 2004, Emerging infectious diseases.
[16] Yanchen Zhou,et al. Protease inhibitors targeting coronavirus and filovirus entry , 2015, Antiviral Research.
[17] G. Gao,et al. Structural Basis for Coronavirus-mediated Membrane Fusion , 2004, Journal of Biological Chemistry.
[18] R. Baric,et al. Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses , 2016, Immunity.
[19] Malik Peiris,et al. Aetiology: Koch's postulates fulfilled for SARS virus , 2003, Nature.
[20] L. Lai,et al. Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein , 2004, Biochemical and Biophysical Research Communications.
[21] Shibo Jiang,et al. A Conformation-Dependent Neutralizing Monoclonal Antibody Specifically Targeting Receptor-Binding Domain in Middle East Respiratory Syndrome Coronavirus Spike Protein , 2014, Journal of Virology.
[22] Zhiwei Chen,et al. Epithelial Cells Lining Salivary Gland Ducts Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the Upper Respiratory Tracts of Rhesus Macaques , 2011, Journal of Virology.
[23] R. L. Roper,et al. SARS vaccines: where are we? , 2009, Expert review of vaccines.
[24] Jincun Zhao,et al. Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models. , 2018, Journal of thoracic disease.
[25] Jian-Piao Cai,et al. Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset , 2015, The Journal of infectious diseases.
[26] A. Abbas,et al. Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein , 2017, Scientific Reports.
[27] W. Wimley,et al. Identification and Characterization of the Putative Fusion Peptide of the Severe Acute Respiratory Syndrome-Associated Coronavirus Spike Protein , 2005, Journal of Virology.
[28] A. Gambotto,et al. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice , 2014, Vaccine.
[29] Shibo Jiang,et al. Current advancements and potential strategies in the development of MERS-CoV vaccines , 2014, Expert review of vaccines.
[30] Shibo Jiang,et al. Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design , 2006, Journal of Virology.
[31] Yi Shi,et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 , 2013, Nature.
[32] H. Kita,et al. Effects of respiratory syncytial virus infection and major basic protein derived from eosinophils in pulmonary alveolar epithelial cells (A549) , 2011, Cell biology international.
[33] M. McNutt,et al. Pathogenetic mechanisms of severe acute respiratory syndrome , 2007, Virus Research.
[34] Kwok-Hung Chan,et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. , 2013, The Journal of general virology.
[35] K. Modjarrad. MERS-CoV vaccine candidates in development: The current landscape , 2016, Vaccine.
[36] R. Baric,et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus , 2015, Proceedings of the National Academy of Sciences.
[37] K. Subbarao,et al. Aged BALB/c Mice as a Model for Increased Severity of Severe Acute Respiratory Syndrome in Elderly Humans , 2005, Journal of Virology.
[38] Shibo Jiang,et al. The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.
[39] M. Peiris,et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro , 2006, Vaccine.
[40] R. Wunderink,et al. MERS, SARS and other coronaviruses as causes of pneumonia , 2017, Respirology.
[41] J. A. Comer,et al. A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[42] R. Crystal,et al. Resolution of Primary Severe Acute Respiratory Syndrome-Associated Coronavirus Infection Requires Stat1 , 2004, Journal of Virology.
[43] T. Greenough,et al. Efficient Replication of Severe Acute Respiratory Syndrome Coronavirus in Mouse Cells Is Limited by Murine Angiotensin-Converting Enzyme 2 , 2004, Journal of Virology.
[44] B. Murphy,et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.
[45] M. Reiter,et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses , 2005, Vaccine.
[46] S. El-Kafrawy,et al. Evidence for camel-to-human transmission of MERS coronavirus. , 2014, The New England journal of medicine.
[47] Yuan Zhang,et al. A molecular docking model of SARS-CoV S1 protein in complex with its receptor, human ACE2 , 2005, Computational Biology and Chemistry.
[48] J. Peiris,et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome , 2003, The Lancet.
[49] V. Brusic,et al. SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens , 2006, Virology.
[50] R. Brunham,et al. Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. , 2006, The Journal of general virology.
[51] S. Qiu,et al. An Exposed Domain in the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Induces Neutralizing Antibodies , 2004, Journal of Virology.
[52] Albert D. M. E. Osterhaus,et al. SARS virus infection of cats and ferrets , 2003, Nature.
[53] G. Gao,et al. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection , 2016, Vaccine.
[54] R. Baric,et al. Crystal Structure of the Receptor-Binding Domain from Newly Emerged Middle East Respiratory Syndrome Coronavirus , 2013, Journal of Virology.
[55] Jincun Zhao,et al. Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. , 2011, The Journal of clinical investigation.
[56] B. Prabhakar,et al. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse® , 2006, Virology.
[57] Z. Memish,et al. An Observational, Laboratory-Based Study of Outbreaks of Middle East Respiratory Syndrome Coronavirus in Jeddah and Riyadh, Kingdom of Saudi Arabia, 2014 , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[58] D. Cummings,et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. , 2013, The New England journal of medicine.
[59] Yonggang Liu,et al. Civets Are Equally Susceptible to Experimental Infection by Two Different Severe Acute Respiratory Syndrome Coronavirus Isolates , 2005, Journal of Virology.
[60] Lisa E. Gralinski,et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence , 2015, Nature Medicine.
[61] Zhènglì Shí,et al. Origin and evolution of pathogenic coronaviruses , 2018, Nature Reviews Microbiology.
[62] H. Feldmann,et al. Domestic Pig Unlikely Reservoir for MERS-CoV , 2017, Emerging infectious diseases.
[63] R. Baric,et al. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease , 2007, Virus Research.
[64] R. Brunham,et al. Severe acute respiratory syndrome (SARS): a year in review. , 2005, Annual review of medicine.
[65] Jing Xie,et al. Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates , 2016, ACS infectious diseases.
[66] A. Curns,et al. Response to Emergence of Middle East Respiratory Syndrome Coronavirus, Abu Dhabi, United Arab Emirates, 2013–2014 , 2016, Emerging infectious diseases.
[67] R. Proulx,et al. Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets , 2004, Journal of Virology.
[68] I. Sola,et al. Engineering a Replication-Competent, Propagation-Defective Middle East Respiratory Syndrome Coronavirus as a Vaccine Candidate , 2013, mBio.
[69] Ulas Bagci,et al. Evaluation of candidate vaccine approaches for MERS-CoV , 2015, Nature Communications.
[70] Shibo Jiang,et al. A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity , 2006, Biochemical and Biophysical Research Communications.
[71] J. McLellan,et al. Host Species Restriction of Middle East Respiratory Syndrome Coronavirus through Its Receptor, Dipeptidyl Peptidase 4 , 2014, Journal of Virology.
[72] K. Subbarao,et al. pH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell Transfer through DC-SIGN , 2004, Journal of Virology.
[73] K. Holmes,et al. SARS-associated coronavirus. , 2003, The New England journal of medicine.
[74] W. Marasco,et al. An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus , 2005, The Journal of pathology.
[75] F. Lai,et al. Acute renal impairment in coronavirus-associated severe acute respiratory syndrome , 2005, Kidney International.
[76] S. Perlman,et al. Complete Protection against Severe Acute Respiratory Syndrome Coronavirus-Mediated Lethal Respiratory Disease in Aged Mice by Immunization with a Mouse-Adapted Virus Lacking E Protein , 2013, Journal of Virology.
[77] Fang Li,et al. Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies , 2014, Journal of Virology.
[78] R. Baric,et al. Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge , 2008, Journal of Virology.
[79] Michelle M. Packard,et al. Severe Acute Respiratory Syndrome Coronavirus Infection of Mice Transgenic for the Human Angiotensin-Converting Enzyme 2 Virus Receptor , 2006, Journal of Virology.
[80] Mark Chappell,et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.
[81] B. Moss,et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[82] Zuyuan Xu,et al. Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. , 2004, Journal of medical microbiology.
[83] R. Baric,et al. Mouse Dipeptidyl Peptidase 4 Is Not a Functional Receptor for Middle East Respiratory Syndrome Coronavirus Infection , 2014, Journal of Virology.
[84] Amit Kapoor,et al. Middle East Respiratory Syndrome Coronavirus Infection in Dromedary Camels in Saudi Arabia , 2014, mBio.
[85] M. Peiris,et al. Experimental Infection and Response to Rechallenge of Alpacas with Middle East Respiratory Syndrome Coronavirus , 2016, Emerging infectious diseases.
[86] K. Shirato,et al. Middle East Respiratory Syndrome Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2 , 2013, Journal of Virology.
[87] G. Gao,et al. Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge , 2015, EBioMedicine.
[88] Linqi Zhang,et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 , 2013, Cell Research.
[89] K. Subbarao,et al. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine , 2005, Virology.
[90] Susan I Gerber,et al. 2014 MERS-CoV outbreak in Jeddah--a link to health care facilities. , 2015, The New England journal of medicine.
[91] J. Segalés,et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels , 2016, Science.
[92] K. Überla,et al. S Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Mediates Entry into Hepatoma Cell Lines and Is Targeted by Neutralizing Antibodies in Infected Patients , 2004, Journal of Virology.
[93] Wenhui Li,et al. A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2* , 2004, Journal of Biological Chemistry.
[94] T. Greenough,et al. Pneumonitis and Multi-Organ System Disease in Common Marmosets (Callithrix jacchus) Infected with the Severe Acute Respiratory Syndrome-Associated Coronavirus , 2005, The American Journal of Pathology.
[95] Wenhui Li,et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[96] T. Kuiken,et al. Asymptomatic Middle East Respiratory Syndrome Coronavirus Infection in Rabbits , 2015, Journal of Virology.
[97] Marco Vignuzzi,et al. Engineering attenuated virus vaccines by controlling replication fidelity , 2008, Nature Medicine.
[98] Xiaolei Yin,et al. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. , 2004, The Journal of infectious diseases.
[99] Chuan Qin,et al. MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2 , 2016, Nature Microbiology.
[100] D. Dimitrov,et al. The SARS-CoV S glycoprotein: expression and functional characterization , 2003, Biochemical and Biophysical Research Communications.
[101] T. Kuiken,et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets , 2004, The Lancet.
[102] J. Peiris,et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003 , 2003, The Lancet.
[103] Krystal L. Matthews,et al. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. , 2014, The Journal of general virology.
[104] Andrew Pekosz,et al. An immunosuppressed Syrian golden hamster model for SARS-CoV infection , 2008, Virology.
[105] Zhiwei Chen,et al. Rhesus angiotensin converting enzyme 2 supports entry of severe acute respiratory syndrome coronavirus in Chinese macaques , 2008, Virology.
[106] T. Greenough,et al. Development and Characterization of a Severe Acute Respiratory Syndrome—Associated Coronavirus—Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice , 2005, The Journal of infectious diseases.
[107] H. Doerr,et al. Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus , 2005, Journal of Virology.
[108] Paul Garner,et al. SARS: Systematic Review of Treatment Effects , 2006, PLoS medicine.
[109] B. Berkhout,et al. Core structure of S2 from the human coronavirus NL63 spike glycoprotein. , 2006, Biochemistry.
[110] B. Bosch,et al. Adenosine Deaminase Acts as a Natural Antagonist for Dipeptidyl Peptidase 4-Mediated Entry of the Middle East Respiratory Syndrome Coronavirus , 2013, Journal of Virology.
[111] Honglin Chen,et al. An Animal Model of MERS Produced by Infection of Rhesus Macaques With MERS Coronavirus , 2013, The Journal of infectious diseases.
[112] Lisa E. Gralinski,et al. A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge , 2011, Journal of Virology.
[113] A. McMichael,et al. T Cell Responses to Whole SARS Coronavirus in Humans1 , 2008, The Journal of Immunology.
[114] S. Harrison,et al. Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.
[115] G. Olinger,et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. , 2014, The Journal of general virology.
[116] Lu Lu,et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor , 2014, Nature Communications.
[117] R. Baric,et al. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome , 2016, Nature Microbiology.
[118] Joshua C. Johnson,et al. Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease , 2015, Virology.
[119] R. Baric,et al. Amino Acid Substitutions in the S2 Subunit of Mouse Hepatitis Virus Variant V51 Encode Determinants of Host Range Expansion , 2007, Journal of Virology.
[120] R. Johnston,et al. Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants , 2006, PLoS medicine.
[121] D. Ho,et al. Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region , 2005, Journal of Virology.
[122] C. Burch,et al. Permissivity of Dipeptidyl Peptidase 4 Orthologs to Middle East Respiratory Syndrome Coronavirus Is Governed by Glycosylation and Other Complex Determinants , 2017, Journal of Virology.
[123] J. Epstein,et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor , 2013, Nature.
[124] R. Baric,et al. Molecular Determinants of Severe Acute Respiratory Syndrome Coronavirus Pathogenesis and Virulence in Young and Aged Mouse Models of Human Disease , 2011, Journal of Virology.
[125] M. Katze,et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques , 2013, Nature Medicine.
[126] T. Greenough,et al. Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters , 2006, The Journal of infectious diseases.
[127] K. Subbarao,et al. Is there an ideal animal model for SARS? , 2006, Trends in Microbiology.
[128] M. St. Claire,et al. Severe Acute Respiratory Syndrome Coronavirus Infection in Vaccinated Ferrets , 2007, The Journal of infectious diseases.
[129] Jianmin Wang,et al. Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset , 2017, The Journal of infectious diseases.
[130] Christian Drosten,et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[131] D. Dimitrov,et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies , 2007, Proceedings of the National Academy of Sciences.
[132] Xinxia Peng,et al. Infection with MERS-CoV Causes Lethal Pneumonia in the Common Marmoset , 2014, PLoS pathogens.
[133] A. Debnath,et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors , 2004, The Lancet.
[134] G. Gao,et al. Crystal Structure of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Fusion Core* , 2004, Journal of Biological Chemistry.
[135] Z. Memish,et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study , 2013, The Lancet Infectious Diseases.
[136] Zhiwei Chen,et al. Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques , 2015, Mucosal Immunology.
[137] K. Subbarao,et al. Animal Models for Sars , 2006, Advances in experimental medicine and biology.
[138] Gary J. Nabel,et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.
[139] Hongbo Hu,et al. Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. , 2005, Journal of combinatorial chemistry.
[140] Chengsheng Zhang,et al. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2 , 2005, The EMBO journal.
[141] Michelle M. Packard,et al. Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice , 2004, Journal of Virology.
[142] R. Brunham,et al. Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. , 2008, The Journal of general virology.
[143] S. Yi,et al. Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[144] Shibo Jiang,et al. Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus , 2015, PloS one.
[145] B. Murphy,et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS , 2004, The Lancet.
[146] R. Baric,et al. Rapid generation of a mouse model for Middle East respiratory syndrome , 2014, Proceedings of the National Academy of Sciences.
[147] K. Yuen,et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein , 2015, Cell Research.
[148] P. T. Ten Eyck,et al. High Prevalence of MERS-CoV Infection in Camel Workers in Saudi Arabia , 2018, mBio.
[149] M. Cho,et al. Specific Asparagine-Linked Glycosylation Sites Are Critical for DC-SIGN- and L-SIGN-Mediated Severe Acute Respiratory Syndrome Coronavirus Entry , 2007, Journal of Virology.
[150] George F. Gao,et al. Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome Coronavirus , 2013, Journal of Virology.
[151] H. Gao,et al. A serological survey on neutralizing antibody titer of SARS convalescent sera , 2005, Journal of medical virology.
[152] P. Woo,et al. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus , 2005, Vaccine.
[153] Jincun Zhao,et al. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice , 2017, Vaccine.
[154] H. Bielefeldt-Ohmann,et al. Infection, Replication, and Transmission of Middle East Respiratory Syndrome Coronavirus in Alpacas , 2016, Emerging Infectious Diseases.
[155] R. Baric,et al. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease , 2012, Nature Medicine.
[156] S. Gilbert,et al. Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology , 2017, Vaccine.
[157] C. Durinx,et al. Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV , 2003, Critical reviews in clinical laboratory sciences.
[158] Jing-Pian Peng,et al. The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization , 2006, Molecular Immunology.
[159] K. To,et al. Active Replication of Middle East Respiratory Syndrome Coronavirus and Aberrant Induction of Inflammatory Cytokines and Chemokines in Human Macrophages: Implications for Pathogenesis , 2013, The Journal of infectious diseases.
[160] K. To,et al. Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response , 2014, Virology.
[161] Christian Drosten,et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.
[162] A. Debnath,et al. Identification of a Receptor-Binding Domain in the S Protein of the Novel Human Coronavirus Middle East Respiratory Syndrome Coronavirus as an Essential Target for Vaccine Development , 2013, Journal of Virology.
[163] J. Segalés,et al. Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels , 2016, Journal of Virology.
[164] David K. Meyerholz,et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice , 2017, Proceedings of the National Academy of Sciences.
[165] Clinical Course and Outcomes of Critically Ill Patients With Middle East Respiratory Syndrome Coronavirus Infection , 2014 .
[166] J. Jan,et al. Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV) , 2005, Journal of biomedical science.
[167] Lu Lu,et al. MERS-CoV spike protein: a key target for antivirals , 2017, Expert opinion on therapeutic targets.
[168] Yan Liu,et al. Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine , 2007, Antiviral therapy.
[169] T. Pan,et al. Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) , 2016, The Journal of Biological Chemistry.
[170] Christian Drosten,et al. Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome , 2003, Science.
[171] Jincun Zhao,et al. T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.
[172] G. Gao,et al. Protective T Cell Responses Featured by Concordant Recognition of Middle East Respiratory Syndrome Coronavirus–Derived CD8+ T Cell Epitopes and Host MHC , 2017, The Journal of Immunology.
[173] D. Meyerholz,et al. Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract , 2016, The American Journal of Pathology.
[174] D. Falzarano,et al. SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.
[175] Jingxin Cao,et al. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets , 2005, Vaccine.
[176] Wenling Wang,et al. Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus , 2018, Emerging Microbes & Infections.
[177] Qingling Zhang,et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways , 2004, The Journal of pathology.
[178] B. Moss,et al. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein , 2005, Virology.
[179] J. Tang,et al. SARS: clinical presentation, transmission, pathogenesis and treatment options. , 2006, Clinical science.
[180] Z. Memish,et al. Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy , 2013, International Journal of Infectious Diseases.
[181] Ralph S. Baric,et al. MyD88 Is Required for Protection from Lethal Infection with a Mouse-Adapted SARS-CoV , 2008, PLoS pathogens.
[182] Yufei Wang,et al. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants , 2016, Journal of Virology.
[183] X. L. Liu,et al. Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China , 2003, Science.
[184] Christian Drosten,et al. The Spike Protein of the Emerging Betacoronavirus EMC Uses a Novel Coronavirus Receptor for Entry, Can Be Activated by TMPRSS2, and Is Targeted by Neutralizing Antibodies , 2013, Journal of Virology.
[185] W. Hong,et al. Amino Acids 1055 to 1192 in the S2 Region of Severe Acute Respiratory Syndrome Coronavirus S Protein Induce Neutralizing Antibodies: Implications for the Development of Vaccines and Antiviral Agents , 2005, Journal of Virology.
[186] H. Feldmann,et al. The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Does Not Replicate in Syrian Hamsters , 2013, PloS one.
[187] Wenhui Li,et al. Conformational States of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Ectodomain , 2006, Journal of Virology.
[188] Chuan Qin,et al. Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways , 2015, The Journal of infectious diseases.
[189] Larissa B. Thackray,et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[190] B. Ni,et al. Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab')2. , 2007, Viral immunology.
[191] Jaap Goudsmit,et al. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.
[192] Baofeng Yang,et al. Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection , 2009, Antiviral Research.
[193] Peter Cameron,et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.
[194] B. Murphy,et al. SARS Vaccine Protective in Mice , 2005, Emerging infectious diseases.
[195] H. Deng,et al. Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome-Associated Coronavirus Infection , 2004, The Journal of Infectious Diseases.
[196] H. Feldmann,et al. Pneumonia from human coronavirus in a macaque model. , 2013, The New England journal of medicine.
[197] Lianfeng Zhang,et al. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. , 2007, Comparative medicine.
[198] Jincun Zhao,et al. Receptor Variation and Susceptibility to Middle East Respiratory Syndrome Coronavirus Infection , 2014, Journal of Virology.
[199] Baoan Yang,et al. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines , 2005, Virology.
[200] T. Kirikae,et al. Fully Human Monoclonal Antibody Directed to Proteolytic Cleavage Site in Severe Acute Respiratory Syndrome (SARS) Coronavirus S Protein Neutralizes the Virus in a Rhesus Macaque SARS Model , 2011, The Journal of infectious diseases.
[201] Y. Guan,et al. Tropism of and Innate Immune Responses to the Novel Human Betacoronavirus Lineage C Virus in Human Ex Vivo Respiratory Organ Cultures , 2013, Journal of Virology.
[202] Noha H Farag,et al. Hospital-Associated Outbreak of Middle East Respiratory Syndrome Coronavirus: A Serologic, Epidemiologic, and Clinical Description , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[203] M. St. Claire,et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys , 2004, Virology.
[204] Huang Xiaojun,et al. The life cycle of SARS coronavirus in Vero E6 cells† , 2004, Journal of medical virology.
[205] Z. Memish,et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia , 2014, International Journal of Infectious Diseases.
[206] Y. Guan,et al. Synthetic Peptides outside the Spike Protein Heptad Repeat Regions as Potent Inhibitors of Sars-Associated Coronavirus , 2005, Antiviral therapy.
[207] R. Crystal,et al. Macaque Model for Severe Acute Respiratory Syndrome , 2004, Journal of Virology.
[208] S. Perlman,et al. Coronaviruses: An Overview of Their Replication and Pathogenesis , 2015, Methods in molecular biology.